Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 3:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 48,563 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: AS+ Clear all

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: Busulfan, Cyclophosphamide; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 6 Months to 65 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: DLBCL, Diffuse Large B-Cell Lymphoma
Interventions: Zilovertamab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Bendamustine, Granulocyte Colony-Stimulating Factor (G-CSF); Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 26
States / cities: Glendale, Arizona • Beverly Hills, California • Walnut Creek, California + 23 more

Conditions: Diabetes Mellitus, Type 1, Type 2
Interventions: Omnipod 5 SmartAdjust 2.0 System, Omnipod 5 System; Device
Lead sponsor: Insulet Corporation; Industry
Eligibility: 2 Years to 70 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 11
States / cities: Los Angeles, California • Santa Barbara, California • Aurora, Colorado + 8 more

Conditions: Advanced Malignancies
Interventions: MBG453, PDR001, Decitabine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 4
States / cities: Baltimore, Maryland • Boston, Massachusetts • Houston, Texas + 1 more

Conditions: Kidney Injury, Acute
Interventions: Sodium Nitrate, Placebo; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Triple Negative Breast Cancer, Triple Negative Breast Cancer (TNBC), Breast Cancer
Interventions: Dexamethasone, Famotidine, Diphenhydramine, Olanzapine, Paclitaxel, Carboplatin, Pembrolizumab, Doxorubicin, Cyclophosphamide; Drug · Biological
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 2
States / cities: Kansas City, Missouri • St Louis, Missouri

Conditions: Hepatocellular Carcinoma
Interventions: Lumason; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Colo-rectal Cancer, Anesthesia
Interventions: IV Medications, placebo; Drug · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Delirium, Surgery-Complications
Interventions: Fluvoxamine, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 60 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Pain, Postoperative
Interventions: Exparel, Bupivacain, Saline; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Postoperative Fistula
Interventions: Teduglutide, Standard of Care; Drug · Other
Lead sponsor: Daniel Dante Yeh; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Alzheimer Disease
Interventions: Family-centered Function-focused Care (Fam-FFC); Behavioral
Lead sponsor: Penn State University; Other
Eligibility: 65 Years and older
Enrollment: 461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 3
States / cities: Lancaster, Pennsylvania • Philadelphia, Pennsylvania • West Chester, Pennsylvania

Conditions: Cardiogenic Shock
Interventions: Istaroxime, Placebo; Drug
Lead sponsor: Windtree Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts • Portland, Oregon

Conditions: Smoking Cessation
Interventions: Propranolol, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 113 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: BI 1015550, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 11
States / cities: Clearwater, Florida • Gainesville, Florida • Kansas City, Kansas + 8 more

Conditions: Neuroendocrine Carcinoma of Pancreas, Carcinoid
Interventions: Gallium Dotatate; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 100 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Human Immunodeficiency Virus, Acquired Immunodeficiency Syndrome
Interventions: Cognitive Rehabilitation; Behavioral
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions: Fuzuloparib , Abiraterone acetate and Prednisone, Fuzuloparib Placebo， Abiraterone acetate and Prednisone; Drug
Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 17
States / cities: Anchorage, Alaska • Tucson, Arizona • Rancho Mirage, California + 13 more

Conditions: Multiple Sclerosis
Interventions: armodafinil; Drug
Lead sponsor: University of Missouri, Kansas City; Other
Eligibility: 18 Years to 60 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Middle Aged
Interventions: MASTERY, Attentional Control; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 45 Years to 64 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non-small Cell Lung Cancer
Interventions: CyberKnife Stereotactic Radiotherapy, Surgery; Radiation · Procedure
Lead sponsor: Accuray Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 14
States / cities: Fresno, California • Colorado Springs, Colorado • Lone Tree, Colorado + 10 more

Conditions: Rheumatoid Arthritis, Vitamin D Deficiency
Interventions: Placebo sugar pill, Ergocalciferol; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pregnancy, Weight Gain
Interventions: Lifestyle Intervention Group, Usual Care Group; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Prenatal Alcohol Exposure, Prenatal Tobacco Exposure, Prenatal Marijuana Exposure
Interventions: Computer tablet-delivered C4H, Person-delivered C4H, Brief Advice; Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 219 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Austin, Texas

Search by objective public record fields.

Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

Omnipod® SmartAdjust 2.0 System Compared to the Omnipod® 5 System in Individuals With Type 1 or Type 2 Diabetes

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Inorganic Nitrate (NaNO3) Prevention of Contrast-Associated Acute Kidney Injury

Dexamethasone De-Escalation in Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer

Accuracy of Contrast-Enhanced Ultrasound for Hepatocellular Carcinoma Post TACE

Does IV Magnesium Improve Quality of Recovery With ERAS Protocols in Laparoscopic Colorectal Surgery?

Mitigating Delirium With Fluvoxamine Treatment for Non-Cardiac Surgery

Bupivacaine Liposomal Injection (Exparel) for Postsurgical Analgesia in Patient Undergoing Laparoscopic Bariatric Surgery

Teduglutide for Enterocutaneous Fistula (ECF)

A Family-centered Intervention for Acutely-ill Persons With Dementia

A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C

Memory Reconsolidation Blockade as a Novel Intervention for Nicotine Dependence

A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers

HIV Medication Adherence in Underserved Populations

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Impact of Armodafinil on Neurocognition and Cognitive Fatigue in Multiple Sclerosis (MS)

Text Messaging to Increase Activity in Midlife

Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer

Treatment of Vitamin D Deficiency in Patients With Rheumatoid Arthritis

Maternal-Offspring Metabolics:Family Intervention Trial

Choices4Health: Intervention to Prevent Substance-exposed Pregnancy